It has been a mixed year for Exozymes Inc. insiders: $6,405 bought by one person and $15,000 sold by one, so more selling than buying overall.
Biggest single buyer: Heltzen Michael, CEO, with roughly $1,900. Notably, at least one C-suite executive was among the buyers.
On the institutional side, 9 funds reported holding EXOZ at the end of Q2 2026, and more funds bought than sold. Zooming out by quarter: Last full quarter: net buying by insiders. Insiders bought in 2 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | Heltzen Michael | CEO | Buy | 100 | $7.50 | $750 | SEC |
| Sep 2, 2026 | Heltzen Michael | CEO | Buy | 250 | $7.52 | $2K | SEC |
| Sep 2, 2026 | Heltzen Michael | CEO | Buy | 251 | $7.35 | $2K | SEC |
| Sep 2, 2026 | Heltzen Michael | CEO | Buy | 250 | $7.60 | $2K | SEC |
| Sep 2, 2026 | Heltzen Michael | CEO | Buy | 4 | $7.58 | $30 | SEC |
| Apr 10, 2026 | Korman Tyler Paz | Executive Officer | Sell | 750 | $10.04 | $8K | SEC |
| Apr 10, 2026 | Korman Tyler Paz | Executive Officer | Sell | 750 | $10.53 | $8K | SEC |
| Jul 2, 2025 | Heltzen Michael | CEO | Buy | 1,040 | $10.22 | $11K | SEC |
In the last 12 months Exozymes Inc. insiders made open-market purchases worth about $6,405 and sales worth about $15,000. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in EXOZ was filed on 2026-09-02.
9 investment managers reported holding EXOZ in SEC Form 13F filings for Q2 2026.
No congressional trades in EXOZ were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).